The trigger system of the KLOE experiment Adinolfi, M; Ambrosino, F; Antonelli, M ...
Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment,
10/2002, Volume:
492, Issue:
1
Journal Article
Peer reviewed
Open access
We present the design of the trigger system for the KLOE experiment at the Frascati
φ-factory DAΦNE. The detector consists of a large-volume drift chamber and a calorimeter both immersed in a
0.52
T
...solenoidal field. The trigger, structured with a first- and a second-decision level, is based on the multiplicity of energy deposits in the calorimeter and of hits in the drift chamber. The selection criteria are described and the efficiency for detecting
φ decays is evaluated using data.
The QCAL tile calorimeter of KLOE Adinolfi, M; Ambrosino, F; Antonelli, M ...
Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment,
05/2002, Volume:
483, Issue:
3
Journal Article
Peer reviewed
The quadrupole tile calorimeters of KLOE (QCAL) are two compact detectors placed close to the interaction point and surrounding the focusing quadrupoles. Their purpose is to increase the hermeticity ...of KLOE calorimetry. Each QCAL consists of a sampling structure of lead plates and scintillator tiles with wavelength shifter (WLS) fibers and mesh photomultiplier readout arranged in 16 azimuthal sectors. The arrangement of WLS fibers allows the measurement of the longitudinal position of the showers from time of flight. In this paper we describe the QCAL design and assembly and present preliminary results obtained with both cosmic rays and photons from K
L decays. The time and energy calibration procedures are also discussed in detail.
The year 2017 was most likely a turning point for the INFN Tier- 1. In fact, on November 9th 2017 early at morning, a large pipe of the city aqueduct, located under the road next to CNAF, broke. As a ...consequence, a river of water and mud flowed towards the Tier-1 data center. The level of the water did not exceed the threshold of safety of the waterproof doors but, due to the porosity of the external walls and the floor, it could find a way into the data center. The flooding almost compromised all the activities and represented a serious threat to future of the Tier-1 itself. The most affected part of the data center was the electrical room, with all switchboards for both power lines and for the continuity systems, but the damages were diffused also to all the IT systems, including all the storage devices and the tape library. After a careful assessment of the damages, an intense recovery activity was launched, aimed not only to restore the services but also to secure data stored on disks and tapes. After nearly two months, in January, we were able to start to reopen gradually all the services, including part of the farm and the storage systems. The long tail of recovery (tapes recovery, second power line) has lasted until the end of May. As a short term consequence we have started a deep consolidation of the data center infrastructure to be able to cope also with this type of incidents; for the medium and long term we are working to move to a new, larger, location, able also to accommodate the foreseen increase of resources for HL-LHC.
Randomized controlled trials (RCTs) have established the efficacy of galcanezumab, an antibody binding calcitonin gene-related peptide (CGRP) ligand, in the preventive treatment of migraine. The ...objective was to summarize real-world data evaluating galcanezumab in the preventive treatment of migraine, to complement RCT results with evidence observed in clinical practice.
A literature search was conducted to identify real-world studies evaluating galcanezumab in the treatment for patients with migraine.
Twenty-five studies were identified; some only evaluated galcanezumab, and others used pooled data from multiple anti-CGRP antibodies. The studies recruited diverse patient populations, including patients who had failed multiple prior preventive therapies. Treatment was associated with significant reductions from baseline in monthly migraine days and monthly headache days by 4.3 to 12.9 and 3.1 to 13.9, respectively. These values were numerically greater than those reported in most galcanezumab RCTs. Significant decreases from baseline were evident within the first month of treatment, and efficacy was maintained throughout the follow-up periods, ranging from 3 to 12 months. Galcanezumab was also associated with improvements in other efficacy end points, including decreased headache pain intensity, reduction in analgesic use, and improvements in daily functioning and quality of life. Functionality scores, as assessed by the Migraine Disability Assessment Scale questionnaire, decreased by 27 to 75 points from baseline at 3 to 12 months. Galcanezumab was associated with a low discontinuation rate and higher rates of persistence compared with standard migraine preventive treatments.
The results provide complementary data that galcanezumab is effective across the diverse patient populations observed in routine clinical practice.
Ageing and neurological disorders can alter the knee functions during activities of daily living. Though active knee exoskeletons have been widely developed in the last decades, only a few are able ...to assist during non-stationary walking and sit-to-stand/stand-to-sit (STS) transitions. First, this work introduces the mechanical, electronic and control design of a novel single-motor Active Knee Orthosis (AKO) with a dual-reduction actuator that selects between two different trains of gears (high torque/low velocity and low torque/high velocity). Other novelties include (i) a symmetrical design, (ii) a torsional spring, (iii) a servo-controlled clutch system and (iv) a non-linear reduction ratio. Then, we present a proof-of-feasibility test with a healthy volunteer performing treadmill walking and STS. The AKO fulfils the requirements of walking and STS tasks in terms of range of motion, torque delivery and angular speed and is able to deliver torque during the application scenario with the two complementary gears. However, an upgraded version should include a simpler clutch design that could lead to a lighter and more reliable exoskeleton with a more adequate weight distribution. The new version will allow for further investigation of the potential of the device and for intense subject testing with healthy volunteers and gait-impaired individuals.
Background
A significant proportion of triptan users exhibit an insufficient response or inadequate tolerability to a triptan, and some may develop a contraindication. Lasmiditan, a selective 5-HT1F ...receptor agonist, may be an option for these individuals. We assessed lasmiditan efficacy in a subgroup of patients in CENTURION (Phase 3 migraine consistency study) who exhibited an insufficient response to triptans, including a subgroup with insufficient response due to efficacy only.
Methods
Patients were randomized to lasmiditan 200 mg for four attacks, lasmiditan 100 mg for four attacks, or placebo for three and lasmiditan 50 mg for one attack. Triptan insufficient responders were pre-defined as patients with insufficient efficacy or tolerability, or who developed a contraindication.
Results
In triptan insufficient responders, lasmiditan was superior to placebo (p < 0.05) for pain freedom beginning at 1 h (both doses); pain relief beginning at 0.5 (200 mg) or 1 h (100 mg); migraine-related disability freedom, much/very much better on the Patient Global Impression of Change, and most bothersome symptom freedom at 2 h; sustained pain freedom; and need for rescue medication. Lasmiditan showed benefit for consistency of effect across attacks for 2-h pain freedom and pain relief. Findings were similar in triptan responders and triptan naïve patients and when the triptan insufficient response definition was based on efficacy only.
Conclusions
Lasmiditan was efficacious across multiple clinically relevant endpoints in the acute treatment of migraine independent of prior response to triptans.
Trial Registration: CENTURION (NCT03670810); SAMURAI (NCT02439320); SPARTAN (NCT02605174)
This letter describes the design and characterization of an upper-limb exoskeleton for post-stroke rehabilitation. The platform interacts with the shoulder and elbow of the user through four active ...joints, driven by series elastic actuators (SEAs) with custom springs to achieve compactness and ease of maintenance. The exoskeleton adopts a passive kinematic chain for aligning the user's and robot joints' rotation axes, and a quick flipping mechanism to enable dual-side use. The pole-placement method based on the dynamic model of the SEA was used to design the low-level controller, to guarantee torque control precision and stability. The joint load due to the robot's gravity is counteracted by using a feed-forward gravity compensation algorithm. Experimental characterization demonstrates the torque control bandwidth up to 10 Hz and highly transparent behavior of the joints (namely, close to null parasitic impedance) at least up to 2 Hz, showing suitability for rehabilitation purposes.
Published appropriate use criteria (AUC) describe patients for whom amyloid positron emission tomography (PET) might be most useful. This study compared the impact of amyloid PET on diagnosis and ...management in subjects likely to either meet or not meet AUC.
Physicians provided a provisional diagnosis and management plan for patients presenting with cognitive decline before and after amyloid PET imaging with florbetapir F 18. Participants were classified as AUC-like or not, based on the prescan diagnosis and demographic features.
In all, 125 of 229 participants (55%) were classified as AUC-like. Sixty-two percent of the AUC-like subjects had a change in diagnosis after scanning compared with 45% of the non-AUC subjects (p = 0.011). Both groups demonstrated high rates of change in their management plans after scanning (88.0% for AUC-like cases, 85.6% for non-AUC cases).
The impact of amyloid imaging on diagnosis and planned management was maintained and, if anything, amplified in AUC-like patients.
The acute antidyskinetic effects of IV amantadine in HD were evaluated. A 2-hour IV infusion of amantadine or placebo was administered to nine patients with HD on two different days in a ...double-blind, randomized crossover fashion. All patients subsequently received oral amantadine unblinded for a 1-year period. A reduction of dyskinesia scores was reported during both IV and oral amantadine treatment (p < 0.05). No significant changes were observed in neuropsychological tests or psychiatric rating scales.
PDF
